secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009166
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports 2022 net loss of $55.3M; cash $251.2M; TYRA-300 in clinic for oncology and achondroplasia
--------------------------------------------------------------------------------

- Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.
- Cash and equivalents $251.2M as of Dec 31, 2022; provides >2 years runway.
- Initiated patient dosing with TYRA-300 in Phase 1/2 SURF301 oncology study in Nov 2022.
- Expanded TYRA-300 development into achondroplasia; IND planned for Phase 2 in 2024.
- FDA cleared IND for TYRA-200 Phase 1 study in FGFR-resistant cholangiocarcinoma; first patient expected 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/0000950170-23-009166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/tyra-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer